Sevelamer Hydrochloride Tablet
Product Images NDC 70748-173

5 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Hydrochloride (NDC 70748-173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (0572e0ce 920f 4db8 8db1 049e577aaadc 01)

01 (0572e0ce 920f 4db8 8db1 049e577aaadc 01)
Chemical structure diagram of Sevelamer hydrochloride polymer. The illustration shows repeating units with primary amine groups, crosslinking groups, and protonated amines, denoted by variables a, b, c, n, and m, representing the polymer's extended network.*
FDA Label Image

02 (0572e0ce 920f 4db8 8db1 049e577aaadc 02)

02 (0572e0ce 920f 4db8 8db1 049e577aaadc 02)
A line graph comparing the percentage of patients achieving various levels of reduction in serum phosphorus (mg/dL) following treatment with Sevelamer Hydrochloride versus an active control. The x-axis shows reduction in serum phosphorus ranging from -4 to 8 mg/dL, and the y-axis shows the percentage of patients with reduction greater than or equal to x, from 0% to 100%. The graph illustrates changes from baseline, indicating worsening or improved reduction.*
FDA Label Image

03 (0572e0ce 920f 4db8 8db1 049e577aaadc 03)

03 (0572e0ce 920f 4db8 8db1 049e577aaadc 03)
A line chart depicting the change from baseline in phosphorus levels over a 52-week study period comparing Sevelamer Hydrochloride to an active control. The chart shows phosphorus change on the y-axis and study weeks on the x-axis, illustrating trends in phosphorus levels across time for both treatments.*
FDA Label Image

06 (0572e0ce 920f 4db8 8db1 049e577aaadc 04)

06 (0572e0ce 920f 4db8 8db1 049e577aaadc 04)
Label for Sevelamer Hydrochloride Tablets, 400 mg strength. The label states the product contains 360 tablets and is labeled by Lupin Pharmaceuticals, Inc. It lists the active ingredient dosage as 400 mg per tablet, provides storage instructions, and includes the manufacturer details: Lupin Pharmaceuticals, Baltimore, MD, and Lupin Limited, Nagpur, India. The label also features a barcode and Rx only statement.*
FDA Label Image

07 (0572e0ce 920f 4db8 8db1 049e577aaadc 05)

07 (0572e0ce 920f 4db8 8db1 049e577aaadc 05)
Label for Sevelamer Hydrochloride Tablets, 800 mg, oral tablets by Lupin Pharmaceuticals, Inc. The label states Rx only and a package count of 180 tablets. Manufacturer information includes Lupin Pharmaceuticals in Baltimore, Maryland, and Lupin Limited in Nagpur, India. Storage and dosage information are partially visible. The label features a barcode and identification numbers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.